Montelukast Sodium

Potent, selective CysLT1 receptor (leukotriene D4) antagonist (Ki = 0.18 nM) 1,2. Displays anti-inflammatory and anti-asthmatic effects. Clinically useful agent for treatment of chronic asthma 3. Attenuates chronic brain injury after focal cerebral ischemia in rodent models 4. Decreases blood brain barrier dysfunction in mouse models 5. Blockade of GPR17 by montelukast elevates neural stem and progenitor proliferation 6.

Catalog ID: N-3028

$114.00 – $456.00

Download Datasheet

  • Product Details
    • Physical State: Powder
    • Temperature Storage: -20°C
    • Temperature Shipping: Ambient
    • Molecular Mass: 608.2

  • References

    1. Lynch, K.R., et al., (1999) Nature, 399 : 789
    2. Jones, T.R., et al., (1995) Can. J. Physiol. Pharmacol., 73 : 191
    3. Reiss, T.F., et al., (1998) Arch. Intern. Med., 158 : 1213
    4. Zhao, R., et al., (2011) J. Pharm. Pharmacol., 63 : 550
    5. Lenz, Q.F., et al., Neuroscience, 26 : 277
    6. Huber, C., et al., Cell Physiol. Biochem., 28 : 793

Related products